**Phase IV Trial Shows Dovato’s Efficacy Comparable to Biktarvy: A New Milestone in HIV Treatment** In the ever-evolving landscape of...

**Understanding the Applicability of Good Manufacturing Practices (GMP)** Good Manufacturing Practices (GMP) are a set of guidelines and regulations that...

**Understanding the Application of Good Manufacturing Practices (GMP)** Good Manufacturing Practices (GMP) are a set of guidelines and regulations that...

**Understanding the Application of Good Manufacturing Practices: Key Guidelines and Timelines** In the realm of manufacturing, particularly within the pharmaceutical,...

**Innovative Test Accurately Predicts Organ Transplant Rejection: A Breakthrough in Transplant Medicine** Organ transplantation has long been a life-saving procedure...

**Innovative Test Accurately Predicts Organ Transplant Rejection Risk** Organ transplantation has long been a beacon of hope for patients with...

**New Test Accurately Predicts Organ Transplant Rejection: A Breakthrough in Transplant Medicine** In the realm of organ transplantation, one of...

**Pharmaceutical Exports Achieve 9.3% Growth in First Quarter of Fiscal Year 2025** The pharmaceutical industry has long been a cornerstone...

**TCBP Administers Sixth Dose in ACHIEVE Clinical Trial for Acute Myeloid Leukemia Patients** In a significant stride towards advancing treatment...

**Title: TCBP Advances ACHIEVE Study with Sixth Patient Dosed for Acute Myeloid Leukemia Treatment** **Introduction** In a significant stride towards...

**TCBP Administers Sixth Patient Dose in ACHIEVE Study for Acute Myeloid Leukemia Treatment** In a significant stride towards advancing treatment...

**TCBP Reports Sixth Patient Dosed in ACHIEVE Study for Acute Myeloid Leukemia Treatment** In a significant stride towards advancing treatment...

**FDA Grants Approval for Epysqli (eculizumab-aagh), a Biosimilar Equivalent to Soliris** In a significant development for the pharmaceutical industry and...

**FDA Grants Approval for Epysqli (eculizumab-aagh) as a Biosimilar to Soliris** In a significant development for the pharmaceutical industry and...

**Carie Pierce, DIA Global Head of Growth, Provides Insights on the 2024 Global Annual Meeting** As the global healthcare landscape...

**DIA’s Global Head of Growth, Carie Pierce, Provides Insights on the 2024 Global Annual Meeting** The Drug Information Association (DIA)...

**LEO Pharma Unveils Pivotal Data from Two Phase III Clinical Trials on Chronic Hand Eczema** In a significant stride towards...

**LEO Pharma Unveils Significant Findings from Two Phase III Clinical Trials on Chronic Hand Eczema** LEO Pharma, a global leader...

**LEO Pharma Unveils Significant Phase III Clinical Trial Results for Chronic Hand Eczema Treatment** In a groundbreaking development for dermatological...

**LEO Pharma Announces Significant Findings From Two Phase III Clinical Trials on Chronic Hand Eczema** LEO Pharma, a global leader...

**Johnson & Johnson’s Carvykti Expected to Achieve Rapid Success in Treating Multiple Myeloma** In the ever-evolving landscape of oncology, Johnson...

**J&J’s Carvykti Set for Rapid Advancement in Multiple Myeloma Treatment** In the ever-evolving landscape of oncology, Johnson & Johnson’s Carvykti...

**Johnson & Johnson’s Carvykti Expected to Achieve Rapid Growth in Multiple Myeloma Treatment** In the ever-evolving landscape of oncology, Johnson...

**Johnson & Johnson’s Carvykti Set for Rapid Advancement in Multiple Myeloma Treatment** In the ever-evolving landscape of oncology, Johnson &...

**FDA Notification: Hikma Pharmaceuticals USA Inc. Expands Voluntary Nationwide Recall of Acetaminophen Injection, 1000mg/100mL (10mg/mL) Bags, One Lot** In a...

**Hikma Pharmaceuticals USA Inc. Expands Nationwide Recall of Acetaminophen Injection 1000mg/100mL Due to Safety Concerns** In a significant development affecting...

**FDA Notification: Hikma Pharmaceuticals USA Inc. Expands Voluntary Nationwide Recall of Acetaminophen Injection, 1000mg/100mL (10mg/mL) Bags, One Lot Affected** In...

**Study Reveals Slight Increase in Adverse Event Risk for Adults with Atopic Dermatitis Using Oral Corticosteroids for Over 90 Days**...

**Research Indicates Slight Increase in Adverse Event Risk for Adults with Atopic Dermatitis Using Oral Corticosteroids for Over 90 Days**...

**Prolonged Oral Corticosteroid Use Linked to Increased Adverse Event Risk in Adults with Atopic Dermatitis, Study Reveals** Atopic dermatitis (AD),...

Insights from Antidote 2023 survey data: Understanding patients’ knowledge of clinical trials

Insights from Antidote 2023 Survey Data: Understanding Patients’ Knowledge of Clinical Trials

Clinical trials play a crucial role in advancing medical research and finding new treatments for various diseases and conditions. However, despite their importance, many patients are unaware of the opportunities and benefits that clinical trials can offer. To gain a better understanding of patients’ knowledge and perceptions of clinical trials, Antidote, a leading digital health company, conducted a comprehensive survey in 2023. The survey aimed to shed light on patients’ awareness, attitudes, and barriers towards participating in clinical trials. The data collected from this survey provides valuable insights that can help improve patient education and engagement in clinical research.

One of the key findings from the Antidote 2023 survey was that a significant number of patients lacked awareness about clinical trials. Out of the 5,000 respondents, only 35% reported having heard of clinical trials before taking the survey. This highlights the need for increased efforts to educate patients about the existence and importance of clinical trials. By raising awareness, more patients can make informed decisions about participating in research studies that may benefit their health and contribute to medical advancements.

Furthermore, the survey revealed that among those who were aware of clinical trials, there were misconceptions and concerns that deterred them from considering participation. Nearly 60% of respondents expressed concerns about potential side effects or risks associated with clinical trials. This fear is understandable, as participants in clinical trials are exposed to experimental treatments that may have unknown effects. Addressing these concerns through transparent communication and providing accurate information about the safety measures in place during clinical trials can help alleviate patient fears and encourage participation.

Another significant finding from the survey was the lack of knowledge about how to find and enroll in clinical trials. Only 20% of respondents reported knowing where to find information about ongoing trials, while a mere 10% were aware of resources available to help them navigate the enrollment process. This highlights the need for improved accessibility and visibility of clinical trial information. Healthcare providers, patient advocacy groups, and digital health platforms can play a crucial role in disseminating information about ongoing trials and providing resources to guide patients through the enrollment process.

The survey also explored the factors that would motivate patients to participate in clinical trials. The most common motivators identified were the potential to access new treatments not yet available to the general public (70% of respondents), the desire to contribute to medical research (65% of respondents), and the opportunity to receive expert medical care (55% of respondents). These findings emphasize the importance of emphasizing the potential benefits of clinical trial participation when educating patients about research opportunities.

In conclusion, the Antidote 2023 survey data provides valuable insights into patients’ knowledge, attitudes, and barriers towards participating in clinical trials. The findings highlight the need for increased awareness, improved patient education, and enhanced accessibility to clinical trial information. By addressing misconceptions, concerns, and knowledge gaps, healthcare providers, researchers, and patient advocacy groups can work together to engage more patients in clinical research. Ultimately, this will lead to better-informed patients, increased participation rates, and accelerated advancements in medical treatments and therapies.